Aytu BioScience Inc (AYTU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aytu BioScience Inc (AYTU) has a cash flow conversion efficiency ratio of -0.119x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.18 Million) by net assets ($35.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AYTU net asset quality score to measure how much of total assets are equity-financed.
Aytu BioScience Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Aytu BioScience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Aytu BioScience Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Aytu BioScience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aytu BioScience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eutilex.Co.Ltd
KQ:263050
|
-0.083x |
|
Conduril - Engenharia S.A
LS:CDU
|
N/A |
|
Zenta Group Company Limited
NASDAQ:ZTG
|
N/A |
|
Rex Industry Bhd
KLSE:9946
|
-0.129x |
|
Western Exploration Inc
V:WEX
|
-0.049x |
|
WITTED MEGACORP OYJ EO 1
F:8OS
|
0.106x |
|
Nitiraj Engineers Limited
NSE:NITIRAJ
|
-0.097x |
|
ECO WAVE POW.GL. SP.ADR/8
F:1KW0
|
N/A |
Annual Cash Flow Conversion Efficiency for Aytu BioScience Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Aytu BioScience Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see AYTU market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $18.97 Million | $-1.94 Million | -0.102x | -103.94% |
| 2024-06-30 | $27.72 Million | $-1.39 Million | -0.050x | +61.57% |
| 2023-06-30 | $39.36 Million | $-5.13 Million | -0.130x | +79.97% |
| 2022-06-30 | $44.31 Million | $-28.82 Million | -0.651x | -244.67% |
| 2021-06-30 | $137.57 Million | $-25.96 Million | -0.189x | +36.80% |
| 2020-06-30 | $95.02 Million | $-28.37 Million | -0.299x | +84.70% |
| 2019-06-30 | $7.09 Million | $-13.83 Million | -1.951x | -64.34% |
| 2018-06-30 | $13.42 Million | $-15.94 Million | -1.187x | +65.66% |
| 2017-06-30 | $4.00 Million | $-13.83 Million | -3.458x | -227.19% |
| 2016-06-30 | $10.09 Million | $-10.66 Million | -1.057x | -148.75% |
| 2015-06-30 | $15.62 Million | $-6.63 Million | -0.425x | +58.54% |
| 2014-06-30 | $5.37 Million | $-5.50 Million | -1.025x | -401.27% |
| 2013-06-30 | $-110.86K | $-37.70K | 0.340x | -37.35% |
| 2012-06-30 | $-69.72K | $-37.85K | 0.543x | -70.19% |
| 2011-06-30 | $-35.59K | $-64.82K | 1.821x | +133.46% |
| 2010-06-30 | $-55.61K | $-43.38K | 0.780x | -77.28% |
| 2009-06-30 | $-13.58K | $-46.63K | 3.433x | +298.92% |
| 2008-06-30 | $25.96K | $-44.80K | -1.726x | -16.26% |
| 2007-06-30 | $18.81K | $-27.92K | -1.484x | -- |
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release o… Read more